Samuel Bates Martin Insider Information
Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.
How do I contact Samuel Bates Martin?
The corporate mailing address for Mr. Martin and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 200-7500 and via email at [email protected]
Has Samuel Bates Martin been buying or selling shares of Celldex Therapeutics?
During the past quarter, Samuel Bates Martin has sold $123,894.00 in shares of Celldex Therapeutics stock. Most recently, Samuel Bates Martin sold 2,738 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $45.25, for a transaction totalling $123,894.50.
Who are Celldex Therapeutics' active insiders?
Are insiders buying or selling shares of Celldex Therapeutics?
In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 430 shares worth mmore than $19,900.40. In the last year, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 23,570 shares worth mmore than $511,578.02. The most recent insider tranaction occured on August, 11th when Freddy A Jimenez SVP bought 430 shares worth more than $19,900.40. Insiders at Celldex Therapeutics own 1.9 % of the company.
Information on this page was last updated on 8/11/2021.
Samuel Bates Martin Insider Trading History at Celldex Therapeutics
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Celldex Therapeutics Company Overview
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
50 Day Range
2 Week Range